AstraZeneca PLC (AZN.L)
21 Nov 2014
|Market Cap (Mil.):||£59,446.24|
|Shares Outstanding (Mil.):||1,262.81|
(The following statement was released by the rating agency) LONDON, November 21 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical AstraZeneca PLC's (AstraZeneca) Long-term Issuer Default Rating (IDR) and senior unsecured rating to 'A+' from 'AA-'. The Outlook is Stable. The downgrade reflects near-term pressure on sales and profitability associated with patent expiry of key drugs, at a time when the company is investing in R&D, future growth opportunities and operational efficienc
(Adds Endo's launch of generic Valcyte and Dr. Reddy's comment)
Nov 20 - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.
Underlying govt bond over midswaps, equivalent to 63.5 bp
* Says receives order from AstraZeneca of about 2.4 million Swedish crowns
LONDON - AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer to launch a new bid. | Video
* Investor day comes 8 days before Pfizer can resume pursuit
MUMBAI - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium, court documents showed.
* Ranbaxy alleges FDA's move violated constitutional rights
Nov 18 - AstraZeneca executives, speaking to reporters: * CEO says hard to comment on read-across from Pfizer/Merck cancer
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (AZN). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ – STARS Reports
"The Economy Matters" Report for AZN: the economy's impact on AZN's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.